BNIP3L and acute myeloid leukemia: When CC-885, E3 ubiquitin ligase, and BNIP3L form the complex, ubiquitinated BNIP3L is degraded in the proteasome, which provides a putative combination of CC-885 with mitochondria-targeted drugs for the treatment of AML [101].